by Maria Zannes | Oct 18, 2024 | Press Releases
SAN ANTONIO, TX (Oct. 18, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with...
by Maria Zannes | Oct 16, 2024 | Press Releases
bioAffinity VP served on expert panel that published new guidance SAN ANTONIO, TX (Oct. 16, 2024) – bioAffinity Technologies’ (Nasdaq: BIAF) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the...
by Maria Zannes | Oct 10, 2024 | Press Releases
Edwards rejoins the Company after serving as interim CFO SAN ANTONIO, TX (Oct. 10, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced...
by Maria Zannes | Oct 9, 2024 | Press Releases
Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO, TX (Oct. 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for...
by Maria Zannes | Sep 18, 2024 | Press Releases
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated...
by Maria Zannes | Aug 23, 2024 | Press Releases
Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO SAN ANTONIO, TX (Aug. 23, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection...
